Therm-SB, Stabilitech’s thermo-stabilization platform,
enables the next generation of vector delivered vaccines and biopharmaceuticals

 

NEXT GENERATION VACCINES

Many of the next generation of vaccines will use a viral vector to deliver a protective antigen. This technology has the advantage of short development timescales, ease of production and relatively low costs. However, many of the viral vectors are thermally unstable and require thermo-stabilization technologies.

NEXT GENERATION BIOPHARMACEUTICALS

Stabilitech is pioneering the use of viral vectors to produce biopharmaceuticals using a similar approach. Our initial trials of using a viral vector to enable protein production may be the beginning of a new technology area that requires our platform technology to succeed.

COLD CHAIN ENHANCEMENT

In addition, our patented viral thermo-stabilization technology is able to give thermal stability to viruses at ambient temperature for long periods, some over 12 months. In future, vaccines may never need to be kept refrigerated.

HUMANITARIAN POTENTIAL

Our core technology has both commercial and humanitarian potential. In the first world, the cold chain can ensure that vaccines are efficacious when they are finally administered.  In the 3rd world, even short temperature excursions may render an entire shipment of vaccines ineffective.  With Stabilitech’s thermo-stabilization technology, a safe and efficacious vaccine can be guaranteed. This may lead the way to eradicating diseases such as measles.

THE TECHNOLOGY

Stabilitech’s technology mimics natural phenomena using well defined non-toxic and inexpensive chemical excipients. The process has been tested on both enveloped and non-enveloped live viruses, a wide range of proteins (including antibodies) and alum adjuvanted subunit vaccines.  It has been shown to successfully stabilise all targets tested.

Novel oral protein therapeutic
Multi-strain influenza vaccine
VZV product exempler
Reduce antigen requirement
by up to 99%
Thermally stable vaccines
Faster onset of immunity
using less vaccine

Recent research alliances – Zoetis

Zoetis is building on a long-term relationship with Stabilitech, a pioneer in thermostable technologies that preserve the efficacy of medicines and vaccines against high and low temperature extremes.

Zoetis and Stabilitech entered a three-year collaboration which will explore the potential of the company’s technologies in biopharmaceuticals and vaccines for animals.

Vaccines and other large biomolecules that could be sterilized, transported and stored at room temperature without significant degradation have the potential to transform animal healthcare – especially in developing countries where access to refrigeration in rural areas is a challenge.

GSK Collaboration, option and license agreement

I am delighted to be able to inform you that we have entered into an option and license agreement with GSK to evaluate Stabilitech’s thermal stability platform technology.

As you know, the Stabilitech platform technology enables development of thermally stable vaccines and biopharmaceuticals.

Under the terms of the research collaboration, GSK has the option to take an exclusive license for use in a defined field. We are not able to disclose further terms of the collaboration.

This is the second project we have worked on with GSK and is further technical validation of our technology and a milestone in our commercialization strategy.